Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
Abstract Background The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients o...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-03-01
|
| Series: | Thrombosis Journal |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12959-018-0161-9 |
| _version_ | 1819026618711015424 |
|---|---|
| author | Hikmat Abdel-Razeq Asem Mansour Hazem Abdulelah Anas Al-Shwayat Mohammad Makoseh Mohammad Ibrahim Mahmoud Abunasser Dalia Rimawi Abeer Al-Rabaiah Rozan Alfar Alaa’ Abufara Alaa Ibrahim Anas Bawaliz Yousef Ismael |
| author_facet | Hikmat Abdel-Razeq Asem Mansour Hazem Abdulelah Anas Al-Shwayat Mohammad Makoseh Mohammad Ibrahim Mahmoud Abunasser Dalia Rimawi Abeer Al-Rabaiah Rozan Alfar Alaa’ Abufara Alaa Ibrahim Anas Bawaliz Yousef Ismael |
| author_sort | Hikmat Abdel-Razeq |
| collection | DOAJ |
| description | Abstract Background The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active cisplatin-based chemotherapy. Methods Medical records and hospital databases were searched for all the patients treated with any cisplatin-based regimen for any kind of cancer. Thrombosis was considered cisplatin-related if diagnosed any time after the first dose and up to 4 weeks after the last. The Khorana risk assessment model was performed in all cases. Results A total of 1677 patients (65.5% males, median age: 50 years) treated with cisplatin-based regimens were identified. Head and neck (22.9%), lung (22.2%), lymphoma and gastric (11.4% each) were the most common primary tumors. Thromboembolic events were reported in 110 (6.6%); the highest was in patients with gastric cancer (20.9%) and the lowest in patients with head and neck cancers (2.3%) and lymphoma (1.6%). Thrombosis included deep vein thrombosis (DVT) in 69 (62.7%), pulmonary embolism (PE) in 18 (16.9%) and arterial thrombosis in 17 (15.6%). A majority (51.1%) of the patients had stage IV disease and only 16% had stage I or II. In a multivariate analysis, significantly higher rates of thrombosis were associated with gastric as the primary tumor, advanced-stage disease, female sex but not age, and the Khorana risk score or type of cisplatin regimen. While the presence of CVC was significantly associated with the risk of thrombosis (p < 0.0001) in the univariate analysis, and such significance was lost in the multivariate analysis (odds ratio, 1.098; 95%CI, 0.603–1.999, p = 0.7599). Conclusions Thromboembolic events in cancer patients on active cisplatin-based chemotherapy were commonly encountered. Gastric cancer, regardless of other clinical variables, was associated with the highest risk. |
| first_indexed | 2024-12-21T05:29:27Z |
| format | Article |
| id | doaj.art-3d114dbac1664614ba0fddcd38468793 |
| institution | Directory Open Access Journal |
| issn | 1477-9560 |
| language | English |
| last_indexed | 2024-12-21T05:29:27Z |
| publishDate | 2018-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Thrombosis Journal |
| spelling | doaj.art-3d114dbac1664614ba0fddcd384687932022-12-21T19:14:34ZengBMCThrombosis Journal1477-95602018-03-011611710.1186/s12959-018-0161-9Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!Hikmat Abdel-Razeq0Asem Mansour1Hazem Abdulelah2Anas Al-Shwayat3Mohammad Makoseh4Mohammad Ibrahim5Mahmoud Abunasser6Dalia Rimawi7Abeer Al-Rabaiah8Rozan Alfar9Alaa’ Abufara10Alaa Ibrahim11Anas Bawaliz12Yousef Ismael13Department of Internal Medicine, King Hussein Cancer CenterRadiology, King Hussein Cancer CenterDepartment of Internal Medicine, King Hussein Cancer CenterDepartment of Internal Medicine, King Hussein Cancer CenterDepartment of Internal Medicine, King Hussein Cancer CenterDepartment of Internal Medicine, King Hussein Cancer CenterDepartment of Internal Medicine, King Hussein Cancer CenterScientific and Reseaerch Office, King Hussein Cancer CenterPharmacy, King Hussein Cancer CenterDepartment of Internal Medicine, King Hussein Cancer CenterDepartment of Internal Medicine, King Hussein Cancer CenterRadiology, King Hussein Cancer CenterDepartment of Internal Medicine, King Hussein Cancer CenterRadiation Oncology, King Hussein Cancer CenterAbstract Background The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active cisplatin-based chemotherapy. Methods Medical records and hospital databases were searched for all the patients treated with any cisplatin-based regimen for any kind of cancer. Thrombosis was considered cisplatin-related if diagnosed any time after the first dose and up to 4 weeks after the last. The Khorana risk assessment model was performed in all cases. Results A total of 1677 patients (65.5% males, median age: 50 years) treated with cisplatin-based regimens were identified. Head and neck (22.9%), lung (22.2%), lymphoma and gastric (11.4% each) were the most common primary tumors. Thromboembolic events were reported in 110 (6.6%); the highest was in patients with gastric cancer (20.9%) and the lowest in patients with head and neck cancers (2.3%) and lymphoma (1.6%). Thrombosis included deep vein thrombosis (DVT) in 69 (62.7%), pulmonary embolism (PE) in 18 (16.9%) and arterial thrombosis in 17 (15.6%). A majority (51.1%) of the patients had stage IV disease and only 16% had stage I or II. In a multivariate analysis, significantly higher rates of thrombosis were associated with gastric as the primary tumor, advanced-stage disease, female sex but not age, and the Khorana risk score or type of cisplatin regimen. While the presence of CVC was significantly associated with the risk of thrombosis (p < 0.0001) in the univariate analysis, and such significance was lost in the multivariate analysis (odds ratio, 1.098; 95%CI, 0.603–1.999, p = 0.7599). Conclusions Thromboembolic events in cancer patients on active cisplatin-based chemotherapy were commonly encountered. Gastric cancer, regardless of other clinical variables, was associated with the highest risk.http://link.springer.com/article/10.1186/s12959-018-0161-9CisplatinChemotherapyThrombosisCancer |
| spellingShingle | Hikmat Abdel-Razeq Asem Mansour Hazem Abdulelah Anas Al-Shwayat Mohammad Makoseh Mohammad Ibrahim Mahmoud Abunasser Dalia Rimawi Abeer Al-Rabaiah Rozan Alfar Alaa’ Abufara Alaa Ibrahim Anas Bawaliz Yousef Ismael Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! Thrombosis Journal Cisplatin Chemotherapy Thrombosis Cancer |
| title | Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
| title_full | Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
| title_fullStr | Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
| title_full_unstemmed | Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
| title_short | Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
| title_sort | thromboembolic events in cancer patients on active treatment with cisplatin based chemotherapy another look |
| topic | Cisplatin Chemotherapy Thrombosis Cancer |
| url | http://link.springer.com/article/10.1186/s12959-018-0161-9 |
| work_keys_str_mv | AT hikmatabdelrazeq thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT asemmansour thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT hazemabdulelah thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT anasalshwayat thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT mohammadmakoseh thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT mohammadibrahim thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT mahmoudabunasser thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT daliarimawi thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT abeeralrabaiah thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT rozanalfar thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT alaaabufara thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT alaaibrahim thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT anasbawaliz thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT yousefismael thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook |